Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response and breakthrough infections after Comirnaty vaccination in Schwaz district
2021-002030-16Phase 4Completed
- Sponsor
- Institute of Virology, Medical University of Innsbruck
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Institute of Virology, Medical University of Innsbruck. Primary endpoint: Neutralizing antibody titer level at visit 1. Started Apr 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002030-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002030-16.